Cover Story
By Matthew Bin Han Ong
The graphs make it seem so simple:Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Menin inhibitors emerge as new treatment for advanced AML
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Cedars-Sinai spearheads first national certification program for COE staff at cancer centers